美国难治性抑郁:电休克治疗与药物/心理治疗的成本效益
该研究采用决策分析模型,模拟美国难治性重性抑郁障碍患者4年治疗过程。结果显示,电休克治疗可减少失控抑郁时间,并增加医疗成本;
要点
- 电休克治疗可减少失控抑郁时间占比,从50%降至33%-37%。
- 从卫生经济学角度,建议在2种以上药物/心理治疗失败后考虑电休克治疗。
核心结论
- 对于美国难治性抑郁患者,电休克治疗可能是一种有效且具有成本效益的治疗选择。
- 从卫生经济学角度,电休克治疗应在2种或以上药物/心理治疗失败后考虑。
研究设计与样本
- 决策分析模型,模拟美国难治性重性抑郁障碍患者4年治疗过程,采用美国卫生保健部门视角。
- 模型输入数据来自多项meta分析、随机试验和观察性研究,人群平均年龄40.7岁(SD 13.2),62.2%为女性。
主要发现
- 4年内,电休克治疗使失控抑郁时间从50%生命年降至33%-37%生命年,越早提供改善越大。
- 敏感性分析中第三线电休克治疗仍具有成本效益;至少一种电休克策略具有成本效益的概率为74%-78%,第三线电休克为最优策略的概率为56%-58%。
临床怎么用
- 对于难治性抑郁,在2种或以上药物/心理治疗失败后,可考虑电休克治疗以改善结局。
- 决策时应结合患者具体情况,但卫生经济学数据支持电休克治疗作为后续选择。
局限性
- 研究为决策分析模型,结果依赖于模型假设和输入数据的不确定性。
- 数据来源尽量限于美国非精神病性重性抑郁研究,可能限制外推性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Electroconvulsive therapy (ECT) is a highly effective treatment for depression but is infrequently used owing to stigma, uncertainty about indications, adverse effects, and perceived high cost. OBJECTIVE: To assess the cost-effectiveness of ECT compared with pharmacotherapy/psychotherapy for treatment-resistant major depressive disorder in the United States. DESIGN, SETTING, AND PARTICIPANTS: A decision analytic model integrating data on clinical efficacy, costs, and quality-of-life effects of ECT compared with pharmacotherapy/psychotherapy was used to simulate depression treatment during a 4-year horizon from a US health care sector perspective. Model input data were drawn from multiple meta-analyses, randomized trials, and observational studies of patients with depression. Where possible, data sources were restricted to US-based studies of nonpsychotic major depression. Data were analyzed between June 2017 and January 2018. INTERVENTIONS: Six alternative strategies for incorporating ECT into depression treatment (after failure of 0-5 lines of pharmacotherapy/psychotherapy) compared with no ECT. MAIN OUTCOMES AND MEASURES: Remission, response, and nonresponse of depression; quality-adjusted life-years; costs in 2013 US dollars; and incremental cost-effectiveness ratios. Strategies with incremental cost-effectiveness ratios of $100 000 per quality-adjusted life-year or less were designated cost-effective. RESULTS: Based on the Sequenced Treatment Alternatives to Relieve Depression trial, we simulated a population with a mean (SD) age of 40.7 (13.2) years, and 62.2% women. Over 4 years, ECT was projected to reduce time with uncontrolled depression from 50% of life-years to 33% to 37% of life-years, with greater improvements when ECT is offered earlier. Mean health care costs were increased by $7300 to $12 000, with greater incremental costs when ECT was offered earlier. In the base case, third-line ECT was cost-effective, with an ICER of $54 000 per quality-adjusted life-year. Third-line ECT remained cost-effective in a range of univariate, scenario, and probabilistic sensitivity analyses. Incorporating all input data uncertainty, we estimate a 74% to 78% likelihood that at least 1 of the ECT strategies is cost-effective and a 56% to 58% likelihood that third-line ECT is the optimal strategy. CONCLUSIONS AND RELEVANCE: For US patients with treatment-resistant depression, ECT may be an effective and cost-effective treatment option. Although many factors influence the decision to proceed with ECT, these data suggest that, from a health-economic standpoint, ECT should be considered after failure of 2 or more lines of pharmacotherapy/psychotherapy.
引用
- Ross EL, Zivin K, Maixner DF, et al. Cost-effectiveness of Electroconvulsive Therapy vs Pharmacotherapy/Psychotherapy for Treatment-Resistant Depression in the United States. JAMA Psychiatry. 2018. PMID: 29800956. doi:10.1001/jamapsychiatry.2018.0768
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。